Eisai Buys U.S. Biotech AkaRx With Chinese And Indian Markets In Sight

Eisai plans to acquire U.S. biotech AkaRx for $225 million in a move that will give the Japanese outfit access to AKR-501, a novel small-molecule thrombopoietin mimetic under development to treat thrombocytopenia resulting from viral hepatitis and other problems